Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Hesai Group Q1 2026 Earnings Call - From LiDAR Leader to Spatial Intelligence Pioneer
Hesai Group delivered a strong Q1 2026, with revenue up 30% year-over-year to RMB 681 million and shipments exceeding 471,000 units. The company reaffirmed its full-year LiDAR shipment guidance of 3 t...
- Revenue surged 30% YoY to RMB 681 million, with LiDAR shipments exceeding 471,000 units in Q1 2026.
- Full-year shipment guidance raised to 3 to 3.5 million units, nearly doubling the record 1.6 million delivered in 2025.
- Backlog for LiDAR units now exceeds 6 million, driven by strong demand for the ATX platform and multi-lidar Level 3 architectures.
- +7 more takeaways
MakeMyTrip FY2026 Earnings Call - AI & Domestic Shift Offset Geopolitical Headwinds
MakeMyTrip delivered steady growth in FY2026 despite a volatile year marked by the West Asia conflict and rising fuel costs. The company's domestic business proved resilient, driven by a structural sh...
- Gross bookings reached a record $10.4 billion in FY2026, compounding at roughly 34% over four years, driven by post-pandemic recovery and structural shifts in Indian consumer behavior.
- Domestic travel remained resilient amid the West Asia conflict, with management shifting focus to eastbound international and domestic destinations to mitigate headwinds.
- AI is central to MakeMyTrip's strategy, with its conversational AI agent Myra handling over 80,000 conversations daily and driving a 10% higher conversion rate compared to traditional search journeys.
- +7 more takeaways
Antalpha Q1 2026 Earnings Call - Record 0 Loss Amid 52% Revenue Growth and Strategic Pivot to AI and Yield
Antalpha delivered a quarter of disciplined execution despite a brutal crypto market backdrop. Revenue surged 52% year-over-year to $20.7 million, driven by a resilient lending book that has maintaine...
- Revenue surged 52% year-over-year to $20.7 million, defying the broader crypto market downturn.
- Antalpha maintains a pristine record of zero principal losses since inception, validating its risk-first, overcollateralization model.
- Major borrower Canaan Inc. repaid approximately $530 million of its loan balance, reducing the total loan book by 3% but demonstrating borrower liquidity and credit health.
- +7 more takeaways
Relmada Therapeutics Q1 2026 Earnings Call - Secures $160M Financing and Advances NDV-01 Toward Mid-2026 Phase III Initiation
Relmada Therapeutics entered Q1 2026 with a fortified balance sheet and a clear path to Phase III. The company closed a $160 million private placement, lifting its cash position to $234 million and ex...
- Relmada closed a $160 million private placement in March 2026, increasing its cash balance to $234 million and providing sufficient runway to fund operations through 2029.
- The company remains on track to initiate the Phase III RESCUE registrational program for NDV-01 in mid-2026, following successful FDA alignment on the trial design.
- NDV-01 demonstrated a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer patients, with a durable 80% complete response rate in the BCG-unresponsive subgroup.
- +7 more takeaways
a.k.a. Brands Q1 2026 Earnings Call - Margin Expansion Signals Structural Turnaround
a.k.a. Brands delivered a Q1 2026 beat on net sales and Adjusted EBITDA, driven by a 180 basis point gross margin expansion that underscores the success of its multi-year inventory reset and test-and-...
- Net sales reached $132.5 million, up 3% year-over-year, and Adjusted EBITDA came in at $5.1 million, ahead of management expectations.
- Underlying gross margin expanded 180 basis points to 59%, driven by improved inventory discipline, stronger full-price sell-through, and the continued rollout of the test-and-repeat model, primarily within the streetwear brands.
- The company recognized a $25.8 million receivable from the reversal of IEEPA tariffs following the Supreme Court decision, though it also recorded a $12 million write-down on legacy streetwear inventory to align with its new buying model.
- +7 more takeaways
MicroVision Q1 2026 Earnings Call - Commercial Traction Returns After Luminar Integration
MicroVision's first quarter 2026 results mark a decisive pivot from experimental development to commercial execution. The company successfully integrated the Luminar and Scantinel acquisitions, consol...
- Revenue increased 50% year-over-year to $0.9 million, with 75% attributed to Luminar-acquired long-range sensors, signaling immediate commercial value from the acquisition.
- Gross margins surged to 39% in Q1, up from 7% in the prior year, with full-year guidance raised to 35%-40% as supply agreements are optimized.
- The company successfully integrated Luminar and Scantinel assets, consolidating all manufacturing into a single Orlando facility to streamline operations and reduce costs.
- +9 more takeaways
Spire Global Q1 2026 Earnings Call - RFGL Converts to Revenue, 50% Full-Year Growth Unchanged
Spire Global delivered a strong first quarter, beating guidance on both revenue and adjusted EBITDA while reaffirming its 50% full-year growth trajectory. The company is pivoting from pipeline promise...
- Q1 2026 revenue beat the high end of guidance, driven by civil government weather data purchases and strong RFGL momentum.
- Core revenue (ex-maritime) grew 13% year-over-year, while full-year 2026 revenue guidance of $75M-$85M (50% growth) remains unchanged.
- RFGL is no longer a technical milestone; five new US orders and three international customers signed, with revenue generation now active.
- +7 more takeaways
Off The Hook Q1 2026 Earnings Call - Record Revenue Driven by Brokerage Scale and AI Infrastructure
Off The Hook reported record Q1 2026 revenue of $29.8 million, up 9.6% year-over-year, fueled by a 46% surge in unit volume to 127 boats and aggressive expansion of its brokerage network. The company ...
- Record Q1 2026 revenue of $29.8 million, up 9.6% year-over-year, driven by higher inventory utilization and brokerage growth.
- Unit volume surged 46% to 127 boats sold, with brokerage transactions accounting for 60 units and wholesale for 60 units.
- Total transaction value reached $61.5 million, with an average selling price of $500,000 and an average gross profit of nearly 11%.
- +9 more takeaways
Longeveron Q1 2026 Earnings Call - FDA Shifts HLHS Primary Endpoint, Management Pivots to Asset-Light Licensing Model
Longeveron’s first quarter results underscore a company in transition. CEO Stephen Willard, who took the helm in February, is steering the biotech toward an asset-light, partnership-driven model as it...
- CEO Stephen Willard, appointed in February 2026, is executing a strategic pivot to an asset-light, partnership-driven model focused on licensing laromestrocel across all four development programs.
- Longeveron secured new investment capital from premier life sciences funds including Coastlands Capital, Janus Henderson Investors, Logos Capital, and Kalehua Capital.
- The company is transitioning to a capital-efficient operating model to extend its runway while prioritizing near-term clinical catalysts, particularly the ELPIS II trial data readout in August 2026.
- +7 more takeaways
Dyadic International Q1 2026 Earnings Call - Revenue Jumps 182% as Products Enter Commercial Channels
Dyadic International’s Q1 2026 results mark a decisive shift from platform development to commercial execution. Revenue surged 182% year-over-year to $1.1 million, driven by early product shipments, l...
- Total revenue reached $1.1 million in Q1 2026, up 182% from $394,000 in Q1 2025, reflecting early commercialization across multiple product lines.
- Proliant Health launched AlbuFree DX, a recombinant human albumin produced on Dyadic’s platform, generating profit-sharing revenue and validating third-party commercial adoption.
- OEM distribution agreement with IBT Bioservices expanded market reach, with initial shipments of DNase I and bovine transferrin already underway.
- +7 more takeaways